Ebselen Potentially Alleviates Cardiomyopathy in Iron-Overloaded Thalassemia
Researchers sought to determine whether ebselen would alleviate cardiomyopathy in patients with iron-overloaded thalassemia.
Diagnosis & Disease Information
Study IDs Factors Explaining Inequity in CVD Mortality in Cancer Survivors
Neighborhood socioeconomic status was strongest mediator, with insurance ranking second.
Researchers Develop Reliable Predictor for Perioperative Diagnosis of Acquired VWS in Infants With Congenital Heart Disease
Researchers sought to investigate diagnostic tools of acquired VWS compared with multimer analysis as diagnostic criterion standard.
Longitudinal Strain May Help Identify Subclinical Myocardial Dysfunction in Beta-Thalassemia Major
Researchers sought to determine whether longitudinal strain with conventional TTE parameters could identify subclinical myocardial dysfunction associated with iron overload in thalassemia.
Reduced Exercise Capacity Associated With Cardiac Iron Overload in Beta-Thalassemia Major
Researchers sought to evaluate potential causes of exercise limitation in patients with beta-thalassemia.
DMT for Sickle Cell Anemia Started in Childhood May Prevent Myocardial Fibrosis
Researchers sought to determine whether early initiation of DMT in childhood would prevent myocardial fibrosis in patients with sickle cell anemia.
Modified Cardiac Rehab May Cut Mortality Risk for Stroke Survivors
As part of stroke recovery program, modified cardiac rehab may lower all-cause one-year mortality, improve overall and cardiovascular function.
Risk of Cardiotoxicity With Doxorubicin for DLBCL Does Not Include Ischemic Heart Disease, Stroke
A study compared patients with diffuse large B-cell lymphoma with a 1:10 cohort from the general population to determine the risk of cardiovascular events in patients receiving doxorubicin-containing regimens.
Risk for Myocarditis Low After Third Dose of BNT162b2 Vaccine
Incidence of myocarditis among young men estimated to be 6.43 and 11.25 per 100,000 vaccines in the week, two weeks after third dose.
Reduced Cardiovascular Morbidity Seen in Patients With Hemophilia
Researchers sought to determine the incidence of fatal and nonfatal CVD during 5 years of follow up in adults with hemophilia.
- Loading...
Loading...
Next post in Bleeding Disorders
Loading... 
Loading...